Ziopharm Receives FDA Clearance for IND with the National Cancer Institute
Ziopharm Oncology (ZIOP) announced on June 11 that the FDA approved an investigational new drug (IND) application as part of a research and development project the company has with the National Cancer Institute. They will now begin clinical trials in solid tumors to evaluate T-cell receptor (TCR) T-cell therapy that uses Ziopharm’s Sleeping Beauty platform. This platform genetically modifies T-cells to help the body combat cancers.
Sonal issued an alert at 8:00 am. Ziopharm opened for trading at $4.22. The stock price rose throughout the day, and the run upwards continued over the next four trading sessions. Ziopharm closed at $5.72 on June 17 for a gain of 35.5%.
If you want to learn more about trading on clinical trial results, visit the Knowledge Center.
To see the latest weekly webinar, you can visit our Live Webinar page.
Subscribe here if you would like to start receiving these signals in real-time and start trading!